Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche

Frontiers in Immunology

Volumn 8, Issue MAR, 2017, Pages

  Chillemi, Antonella ^a   Quarona, Valeria ^a   Antonioli, Luca ^b   Ferrari, Davide ^c   Horenstein, Alberto L ^a   Malavasi, Fabio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Adenosine; CD38; Ectoenzymes; Microvesicles; Multiple myeloma therapy

Indexed keywords

5' NUCLEOTIDASE; CD38 ANTIGEN; ECTO NUCLEOTIDASE; PEPTIDES AND PROTEINS; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; DISEASE MODEL; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; HYPOXIA; MULTIPLE MYELOMA; NUCLEOTIDE METABOLISM; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 85017100998     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00305     Document Type: Article

References (32)

1. Plattner H, Verkhratsky A. Inseparable tandem: evolution chooses ATP and Ca2+ to control life, death and cellular signalling. Philos Trans R Soc Lond B Biol Sci (2016) 371(1700):20150419. doi: 10.1098/rstb.2015.0419
2. Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, et al. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Ann N Y Acad Sci (2015) 1335:10-22. doi:10.1111/nyas.12485
3. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 13(12):842-57. doi:10.1038/nrc3613
4. Ferrero E, Lo Buono N, Horenstein AL, Funaro A, Malavasi F. The ADP-ribosyl cyclases-the current evolutionary state of the ARCs. Front Biosci (Landmark Ed) (2014) 19:986-1002. doi:10.2741/4262
5. Lee HC. Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization. J Biol Chem (2012) 287(38):31633-40. doi:10.1074/jbc.R112.349464
6. Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein AL, Ortolan E, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev (2008) 88(3):841-86. doi:10.1152/physrev.00035.2007
7. Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology (2013) 2(9):e26246. doi:10.4161/onci.26246
8. Melendez-Hevia E, Montero-Gomez N, Montero F. From prebiotic chemistry to cellular metabolism-the chemical evolution of metabolism before Darwinian natural selection. J Theor Biol (2008) 252(3):505-19. doi:10.1016/j.jtbi.2007.11.012
9. Horenstein AL, Quarona V, Toscani D, Costa F, Chillemi A, Pistoia V. Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma. Mol Med (2016) 22:694-704. doi:10.2119/molmed.2016.00198
10. Fredholm BB, Johansson S, Wang YQ. Adenosine and the regulation of metabolism and body temperature. Adv Pharmacol (2011) 61:77-94. doi:10.1016/B978-0-12-385526-8.00003-5
11. van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood (2016) 127(6):681-95. doi:10.1182/blood-2015-10-646810
12. Garber K. Cancer anabolic metabolism inhibitors move into clinic. Nat Biotechnol (2016) 34(8):794-5. doi:10.1038/nbt0816-794
13. Curi R, Newsholme P, Newsholme EA. Metabolism of pyruvate by isolated rat mesenteric lymphocytes, lymphocyte mitochondria and isolated mouse macrophages. Biochem J (1988) 250(2):383-8. doi:10.1042/bj2500383
14. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell (2006) 9(6):425-34. doi:10.1016/j.ccr.2006.04.023
15. Ohta A, Diwanji R, Kini R, Subramanian M, Ohta A, Sitkovsky M. In vivo T cell activation in lymphoid tissues is inhibited in the oxygen-poor microenvironment. Front Immunol (2011) 2:27. doi:10.3389/fimmu.2011.00027
16. Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol (2016) 29:7-16. doi:10.1016/j.coph.2016.04.001
17. Menkin V. Biology of inflammation; chemical mediators and cellular injury. Science (1956) 123(3196):527-34. doi:10.1126/science.123.3196.527
18. Reinisch A, Majeti R. Sticking it to the niche: CD98 mediates critical adhesive signals in AML. Cancer Cell (2016) 30(5):662-4. doi:10.1016/j.ccell.2016.10.014
19. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 19(6):355-67. doi:10.1016/j.molmed.2013.03.005
20. Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, et al. NAD(+)-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model. Cells (2015) 4(3):520-37. doi:10.3390/cells4030520
21. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 324(5930):1029-33. doi:10.1126/science.1160809
22. Bruzzone S, Guida L, Zocchi E, Franco L, De Flora A. Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD+ fluxes in intact cells. FASEB J (2001) 15(1):10-2. doi:10.1096/fj.00-0566fje
23. Woehrle T, Yip L, Elkhal A, Sumi Y, Chen Y, Yao Y. Pannexin-1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T-cell activation at the immune synapse. Blood (2010) 116(18):3475-84. doi:10.1182/blood-2010-04-277707
24. Hubert S, Rissiek B, Klages K, Huehn J, Sparwasser T, Haag F. Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway. J Exp Med (2010) 207(12):2561-8. doi:10.1084/jem.20091154
25. Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, et al. CD56brightCD16-NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol (2015) 195(3):965-72. doi:10.4049/jimmunol.1500591
26. Morandi F, Morandi B, Horenstein AL, Chillemi A, Quarona V, Zaccarello G, et al. A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget (2015) 6(28):25602-18. doi:10.18632/oncotarget.4693
27. Arendt BK, Walters DK, Wu X, Tschumper RC, Jelinek DF. Multiple myeloma dell-derived microvesicles are enriched in CD147 expression and enhance tumor cell proliferation. Oncotarget (2014) 5(14):5686-99. doi:10.18632/oncotarget.2159
28. Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest (2016) 126(4):1216-23. doi:10.1172/JCI81136
29. Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol (2016) 7:109. doi:10.3389/fimmu.2016.00109
30. Antonioli L, Blandizzi C, Malavasi F, Ferrari D, Hasko G. Anti-CD73 immunotherapy: a viable way to reprogram the tumor microenvironment. Oncoimmunology (2016) 5(9):e1216292. doi:10.1080/2162402X.2016.1216292
31. van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev (2016) 270(1):95-112. doi:10.1111/imr.12389
32. Karakasheva TA, Waldron TJ, Eruslanov E, Kim SB, Lee JS, O'Brien S, et al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res (2015) 75(19):4074-85. doi:10.1158/0008-5472.CAN-14-3639